Zobrazeno 1 - 10
of 59
pro vyhledávání: ''
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Autor:
Takako Eguchi Nakajima, Keiko Minashi, Shuichi Hironaka, Tomohiro Nishina, Takeharu Yamanaka, Takeshi Kajiwara, Naoki Izawa, Kei Muro, Yutaka Kawakami, Yuichiro Hayashi, Shigenori Kadowaki
Publikováno v:
Clinical Cancer Research. 27:1029-1036
Purpose: We conducted a phase I/II study to investigate the safety and efficacy of nivolumab with paclitaxel plus ramucirumab. Patients and Methods: Patients with advanced gastric cancer (AGC) refractory to first-line chemotherapy were included. Pati
Autor:
Daniel C. Danila, Thompson N. Doman, Jonathan Landa, David Schaer, Shanu Modi, Elizabeth A. Comen, Matthew Adamow, Jill S. Gluskin, Susan F. Slovin, Michael J. Morris, Suhyun Kang, Manisha Brahmachary, Sonya C. Chapman, David M. J. Hoffman, Rachel Sanford, Jeremy C. Durack, Josef J. Fox, Michelle Carlsen, Ruslan D. Novosiadly, Philomena McAndrew, John S. Kauh, Dana E. Rathkopf, Courtney M. Tate, Danni Yu, Karen A. Autio, Victoria S. Blinder, Phillip Wong, Praneet Kang, Christopher A. Klebanoff, Heather L. McArthur
Publikováno v:
Clin Cancer Res
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macropha
Autor:
Xianglin Yuan, Xiang Li, Buhai Wang, Nong Xu, Jian-Ming Xu, Jin Wang, Enxiao Li, Yuxian Bai, Xin Wang
Publikováno v:
Clinical Cancer Research. 26:4542-4550
Purpose: This phase II study (NCT03469557) assessed safety/tolerability and antitumor activity of first-line tislelizumab, a monoclonal antibody against programmed cell death-1, plus chemotherapy in patients with locally advanced/metastatic esophagea
Autor:
Massimo Fantini, Amit Mahipal, Michael A. Morse, Kwong Y. Tsang, Anjum Zaki, B. T. Benjamin Tan, Richard D. Kim, Philip M. Arlen, Jose R. Torrealba, Nilofer S. Azad, Sharon Mavroukakis, Elizabeth Poplin, Muhammad Shaalan Beg
Publikováno v:
Clinical Cancer Research. 26:3557-3564
Purpose: Patients with metastatic colorectal cancer refractory to chemotherapy have limited treatment options. Ensituximab (NEO-102) is a novel chimeric mAb targeting a variant of MUC5AC with specificity to colorectal cancer. Patients and Methods: Si
Autor:
Mohammad Azab, Ursula A. Matulonis, H Hirte, Bristi Basu, Susana Banerjee, John Nemunaitis, Harold N. Keer, Benjamin Schwartz, Deborah K. Armstrong, Patricia S. Braly, Merry Jennifer Markham, Rebecca Kristeleit, Lynda D. Roman, Diane Provencher, Daniela Matei, Sue Naim, Geoff Hall, Aram Oganesian, Simone Jueliger, Sarah P. Blagden, Michael J. Birrer, Sharad A. Ghamande, Kenneth P. Nephew, Angeles Alvarez Secord, Amit M. Oza, Yong Hao, William P. McGuire, Gini F. Fleming
Publikováno v:
Clin Cancer Res
Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a
Autor:
Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li
Publikováno v:
Clinical Cancer Research. 26:1105-1113
Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).
Autor:
Rachael A. Clark, Jessica E. Teague, Anita Giobbie-Hurder, John T. O'Malley, Adèle de Masson, A. Gehad, Nicole R. LeBoeuf, Thomas S. Kupper, E.L. Lowry, Cecilia Larocca, Edward W Seger, David C. Fisher, Phillip M. Devlin
Publikováno v:
Clin Cancer Res
Purpose: Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma. Skin-directed treatments often improve but do not cure mycosis fungoides skin lesions. The purpose of this study was to (i) assess whether remission was associated wi
Autor:
Cristiana A Costa, Todd A. MacKenzie, Anne W. Beaven, Sara R Metzler, Bonnie Toaso, Eric S. Winer, Lynn Shaw, Bassem I. Zaki, Helen Ryan, Youdinghuan Chen, Stephanie P. Yen, Frederick Lansigan, Darcie Findley
Publikováno v:
Clinical Cancer Research. 25:6073-6079
Purpose: Bendamustine and rituximab (BR) has been established as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma (FL). Yttrium-90 Ibritumomab tiuxetan (90YIT) is an effective consolidation strategy after chemotherapy